SG11202104053TA - Compositions and methods for the treatment of estrogen-dependent disorders - Google Patents
Compositions and methods for the treatment of estrogen-dependent disordersInfo
- Publication number
- SG11202104053TA SG11202104053TA SG11202104053TA SG11202104053TA SG11202104053TA SG 11202104053T A SG11202104053T A SG 11202104053TA SG 11202104053T A SG11202104053T A SG 11202104053TA SG 11202104053T A SG11202104053T A SG 11202104053TA SG 11202104053T A SG11202104053T A SG 11202104053TA
- Authority
- SG
- Singapore
- Prior art keywords
- estrogen
- compositions
- treatment
- methods
- dependent disorders
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756946P | 2018-11-07 | 2018-11-07 | |
| PCT/EP2019/080362 WO2020094698A2 (en) | 2018-11-07 | 2019-11-06 | Compositions and methods for the treatment of estrogen-dependent disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104053TA true SG11202104053TA (en) | 2021-05-28 |
Family
ID=68618113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104053TA SG11202104053TA (en) | 2018-11-07 | 2019-11-06 | Compositions and methods for the treatment of estrogen-dependent disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230067378A1 (https=) |
| EP (1) | EP3876943A2 (https=) |
| JP (1) | JP7459086B2 (https=) |
| KR (1) | KR20210100623A (https=) |
| MA (1) | MA54150A (https=) |
| SG (1) | SG11202104053TA (https=) |
| WO (1) | WO2020094698A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| SG11201911599XA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| CA3117092A1 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| AU2020325655B2 (en) * | 2019-08-08 | 2025-09-11 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of estrogen-dependent disorders |
| BR112022023937A2 (pt) * | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| AU2023325806A1 (en) * | 2022-08-16 | 2025-03-06 | Cms Research & Development Pte. Ltd. | Salt type and crystal form of thienopyrimidinone derivative |
| WO2026060502A1 (pt) * | 2024-09-23 | 2026-03-26 | Klautau Leite Ana Paula | Sistema de diagnóstico por imagem da endometriose profunda e/ou adenomiose e método de análise de exames de imagem |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960591B2 (en) | 2000-07-05 | 2005-11-01 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivative |
| EP1591446B1 (en) | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| AU2004257639B2 (en) | 2003-07-07 | 2011-01-06 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| PL1939204T6 (pl) | 2005-10-19 | 2024-03-25 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne |
| JP5337261B2 (ja) | 2010-02-10 | 2013-11-06 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の塩及びその結晶 |
| WO2014042176A1 (ja) * | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| UA123114C2 (uk) | 2016-08-08 | 2021-02-17 | Кіссеі Фармасьютікал Ко., Лтд. | СПОСІБ ЛІКУВАННЯ ЕНДОМЕТРІОЗУ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНІЛ]-2,4-ДІОКСО-1,2,3,4-ТЕТРАГІДРОТІЄНО[3,4-d]ПІРИМІДИН-5-КАРБОНОВОЮ КИСЛОТОЮ |
| SG11201911599XA (en) * | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| AU2018419533A1 (en) * | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
-
2019
- 2019-11-06 SG SG11202104053TA patent/SG11202104053TA/en unknown
- 2019-11-06 MA MA054150A patent/MA54150A/fr unknown
- 2019-11-06 WO PCT/EP2019/080362 patent/WO2020094698A2/en not_active Ceased
- 2019-11-06 EP EP19805904.0A patent/EP3876943A2/en active Pending
- 2019-11-06 US US17/291,192 patent/US20230067378A1/en active Pending
- 2019-11-06 KR KR1020217017190A patent/KR20210100623A/ko not_active Withdrawn
- 2019-11-06 JP JP2021523696A patent/JP7459086B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7459086B2 (ja) | 2024-04-01 |
| JP2022506368A (ja) | 2022-01-17 |
| WO2020094698A2 (en) | 2020-05-14 |
| US20230067378A1 (en) | 2023-03-02 |
| MA54150A (fr) | 2021-09-15 |
| EP3876943A2 (en) | 2021-09-15 |
| KR20210100623A (ko) | 2021-08-17 |
| WO2020094698A3 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298690B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
| SG11202104053TA (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| IL275182A (en) | Preparations and methods for the treatment of metabolic conditions | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| IL258032B (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| IL279634A (en) | Preparations and methods for the treatment and prevention of neurological disorders | |
| IL275985A (en) | Preparations and methods for the treatment of retinal disorders | |
| IL278978A (en) | Preparations and methods for treating eczema | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| IL282455A (en) | Methods and preparations for the treatment of secretory disorders | |
| SG11202000612TA (en) | Methods and compositions for the treatment of melanoma | |
| GB201702603D0 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL290151A (en) | Compositions and methods for treating anal and rectal disorders | |
| HK40060173A (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| HK40075926A (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| IL291184A (en) | Compositions and methods for treating disorders associated with dysfunction or loss of clec16a | |
| ZA202004110B (en) | Compositions and methods for the treatment of metabolic conditions | |
| HK40061263A (en) | Compositions and methods for the treatment of liver disorders | |
| GB201810925D0 (en) | Compositions and methods of treatment | |
| SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
| HK40022768A (en) | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |